115 related articles for article (PubMed ID: 38270175)
1. On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Troisi R; Tito G; Ferraro G; Sica F; Massai L; Geri A; Cirri D; Messori L; Merlino A
Dalton Trans; 2024 Feb; 53(8):3476-3483. PubMed ID: 38270175
[TBL] [Abstract][Full Text] [Related]
2. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Miodragović Đ; Merlino A; Swindell EP; Bogachkov A; Ahn RW; Abuhadba S; Ferraro G; Marzo T; Mazar AP; Messori L; O'Halloran TV
J Am Chem Soc; 2019 Apr; 141(16):6453-6457. PubMed ID: 30943017
[TBL] [Abstract][Full Text] [Related]
3. The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.
Ferraro G; Cirri D; Marzo T; Pratesi A; Messori L; Merlino A
Dalton Trans; 2021 Jan; 50(1):68-71. PubMed ID: 33320144
[TBL] [Abstract][Full Text] [Related]
4. Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity.
Ferraro G; Pratesi A; Cirri D; Imbimbo P; Maria Monti D; Messori L; Merlino A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668605
[TBL] [Abstract][Full Text] [Related]
5. Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.
Miodragović Ð; Qiang W; Sattar Waxali Z; Vitnik Ž; Vitnik V; Yang Y; Farrell A; Martin M; Ren J; O'Halloran TV
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500854
[TBL] [Abstract][Full Text] [Related]
6. Beyond Cisplatin: Combination Therapy with Arsenic Trioxide.
Miodragović Ð; Swindell EP; Waxali ZS; Bogachkov A; O'Halloran TV
Inorganica Chim Acta; 2019 Oct; 496():. PubMed ID: 32863421
[TBL] [Abstract][Full Text] [Related]
7. Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study.
Tolbatov I; Cirri D; Tarchi M; Marzo T; Coletti C; Marrone A; Messori L; Re N; Massai L
Inorg Chem; 2022 Feb; 61(7):3240-3248. PubMed ID: 35137586
[TBL] [Abstract][Full Text] [Related]
8. The role of arsenic in the hydrolysis and DNA metalation processes in an arsenous acid-platinum(ii) anticancer complex.
Marino T; Parise A; Russo N
Phys Chem Chem Phys; 2017 Jan; 19(2):1328-1334. PubMed ID: 27966695
[TBL] [Abstract][Full Text] [Related]
9. Comparative thermal and thermodynamic study of DNA chemically modified with antitumor drug cisplatin and its inactive analog transplatin.
Lando DY; Chang CL; Fridman AS; Grigoryan IE; Galyuk EN; Hsueh YW; Hu CK
J Inorg Biochem; 2014 Aug; 137():85-93. PubMed ID: 24831492
[TBL] [Abstract][Full Text] [Related]
10. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.
Peleg-Shulman T; Najajreh Y; Gibson D
J Inorg Biochem; 2002 Jul; 91(1):306-11. PubMed ID: 12121789
[TBL] [Abstract][Full Text] [Related]
11. The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions.
Brabec V; Pracharova J; Novakova O; Gibson D; Kasparkova J
Dalton Trans; 2015 Feb; 44(8):3573-82. PubMed ID: 25406573
[TBL] [Abstract][Full Text] [Related]
12. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Xin J; Zhang K; Huang J; Luo X; Gong X; Yang Z; Lin H; Shan H; Gao J
Biomater Sci; 2018 Dec; 7(1):262-271. PubMed ID: 30465673
[TBL] [Abstract][Full Text] [Related]
13. Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand.
Frybortova M; Novakova O; Stepankova J; Novohradsky V; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2013 Sep; 126():46-54. PubMed ID: 23770803
[TBL] [Abstract][Full Text] [Related]
14. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.
Gelasco A; Lippard SJ
Biochemistry; 1998 Jun; 37(26):9230-9. PubMed ID: 9649303
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
[TBL] [Abstract][Full Text] [Related]
16. Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog.
Safa Shams Abyaneh F; Eslami Moghadam M; Hossaini Sadr M; Divsalar A
J Biomol Struct Dyn; 2018 Mar; 36(4):893-905. PubMed ID: 28335682
[TBL] [Abstract][Full Text] [Related]
17. Internalization of Ineffective Platinum Complex in Nanocapsules Renders It Cytotoxic.
Vrana O; Novohradsky V; Medrikova Z; Burdikova J; Stuchlikova O; Kasparkova J; Brabec V
Chemistry; 2016 Feb; 22(8):2728-35. PubMed ID: 26789279
[TBL] [Abstract][Full Text] [Related]
18. Theoretical analysis on the transition state of the anticancer drug trans-[PtCl2(isopropylamine)2] and its cis isomer binding to DNA purine bases.
Zhou L
J Phys Chem B; 2009 Feb; 113(7):2110-27. PubMed ID: 19173577
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and transplatin interaction with methionine: bonding motifs assayed by vibrational spectroscopy in the isolated ionic complexes.
Paciotti R; Corinti D; De Petris A; Ciavardini A; Piccirillo S; Coletti C; Re N; Maitre P; Bellina B; Barran P; Chiavarino B; Elisa Crestoni M; Fornarini S
Phys Chem Chem Phys; 2017 Oct; 19(39):26697-26707. PubMed ID: 28876340
[TBL] [Abstract][Full Text] [Related]
20. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach.
Hartinger CG; Tsybin YO; Fuchser J; Dyson PJ
Inorg Chem; 2008 Jan; 47(1):17-9. PubMed ID: 18067289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
